BLASUBCUTANEOUSSOLUTION
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
5/8 — Partial
Cutaquig (immunoglobulin g) by Octapharma is (igg) antibodies against a wide variety of bacterial and viral agents. First approved in 2019.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cutaquig is a subcutaneous immunoglobulin G (IgG) solution containing polyclonal antibodies against a broad spectrum of bacterial and viral pathogens. It is approved for primary humoral immunodeficiency (PI) and works by restoring abnormally low IgG levels to normal range to prevent infections. The drug maintains a subclass distribution proportional to native human plasma.
$2MPart D
PeakAt peak sales lifecycle with modest Part D uptake (254 claims in 2023); growth potential in subcutaneous immunoglobulin segment suggests stable commercial team requirements.
Mechanism of Action
(IgG) antibodies against a wide variety of bacterial and viral agents. It has a distribution of immune globulin subclasses closely proportional to that in native human plasma. The mechanism of action in primary humoral immunodeficiency (PI) has not been fully elucidated; however adequate doses may…
Pharmacologic Class:
Antigen Neutralization
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions
Started Jun 2025
82 enrolled
Healthy Participants
Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.
Started Apr 2023
36 enrolled
Primary Immune Deficiency DisorderSecondary Immune Deficiency
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Started Oct 2021
8 enrolled
IgG4 Related DiseaseIgG4-RD
An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
Started May 2020
200 enrolled
Neuromyelitis Optica Spectrum Disorders
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
Started Sep 2018
30 enrolled
Primary Immunodeficiency DiseaseSecondary Immunodeficiency
Worked on Cutaquig at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.